Vanguard Capital Management
RXRX icon

Vanguard Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Vanguard Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.6M Buy
22,765,940
+521,553
+2% +$1.74M ﹤0.01% 1658
2026
Q1 		$68.3M Buy
+22,244,387
New +$86M ﹤0.01% 1678

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Capital Management's RXRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 2.3% in Q2 2026, buying an estimated $1.74M and bringing the position to 22,765,940 shares worth $83.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

Vanguard Capital Management first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Vanguard Capital Management held 22,765,940 shares of Recursion Pharmaceuticals worth $83.6M as of Q2 2026.
  • Vanguard Capital Management bought 521,553 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.74M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1658 holding.
  • Vanguard Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.